Methods and compositions for wound healing
Methods and compositions comprising combinations of one or more anti-connexin agents and one or more other agents useful for the promotion and/or improvement of wound healing and/or tissue repair.
1. A method for promoting or improving healing of optic nerve or eye tissue in a subject, comprising administering to the subject an anti-connexin agent simultaneously with, separately from or sequentially with a medicament comprising a therapeutically effective amount of an antagonist of VEGF, wherein the connexin agent is an anti-connexin 43 polynucleotide or an anti-connexin 43 peptide or peptidomimetic.
2. A method according to claim 1 , wherein the anti-connexin agent and the VEGF antagonist are administered simultaneously.
3. A method according to claim 1 , wherein the anti-connexin agent and the VEGF antagonist are not administered simultaneously.
4. A method according to claim 1 , wherein the anti-connexin agent and the VEGF antagonist are administered sequentially.
5. A method according to claim 1 , wherein the anti-connexin agent is administered first.
6. A method according to claim 1 , wherein the VEGF antagonist is administered first.
7. The method according to any one of claim 1 , or 2 - 5 , wherein the anti-connexin agent is formulated in a matrix.
8. A method for promoting or improving healing of eye tissue in a subject, comprising administering to the subject an anti-connexin 43 peptide or peptidomimetic simultaneously with, separately from or sequentially with a medicament comprising a therapeutically effective amount of an antagonist of VEGF.
9. A method according to claim 8 , wherein the antagonist of VEGF is an antagonist of VEGF-A.
10. A method according to claim 8 , wherein the anti-connexin 43 peptide or peptidomimetic is from 8 to about 15 amino acids and comprises SRPTEKT (SEQ ID NO:35).
11. A method according to claim 8 , wherein the anti-connexin 43 peptide or peptidomimetic is from 11 to about 13 amino acids and comprises SRPTEKT (SEQ ID NO:35).
12. A method according to claim 10 , wherein the anti-connexin 43 peptide or peptidomimetic is VDCFLSRPTEKT (SEQ.ID.NO: 18).
13. A method according to claim 10 , wherein the anti-connexin 43 peptide or peptidomimetic is SRPTEKTIFII (SEQ.ID.NO: 19).
14. A method according to claim 11 , wherein the anti-connexin 43 peptide or peptidomimetic is VDCFLSRPTEKT (SEQ.ID.NO:18).
15. A method according to claim 11 , wherein the anti-connexin 43 peptide or peptidomimetic is SRPTEKTIFII (SEQ.ID.NO:19).
16. The method according to any one of claim 1 , or 2 - 5 , wherein the anti-connexin agent is formulated in a delayed release preparation, a slow release preparation, an extended release preparation, a controlled release preparation.
17. The method according to any one of claims 8 - 13 , 14 , or, 15 wherein the anti-connexin agent is formulated in a matrix.
18. The method according to any one of claims 8 - 13 , 14 , or, 15 wherein the anti-connexin agent is formulated in a delayed release preparation, a slow release preparation, an extended release preparation, a controlled release preparation.